Iruxol Mono (Collagenase Clostridium Histolyticum, Protease)

Collagenase clostridium histolyticum cleaves the peptide bonds of native collagen and other extracellular matrix proteins within necrotic tissue. This selective proteolysis breaks down the collagenous scaffold of dead tissue while sparing viable cells, thereby facilitating removal of the necrotic material and promoting granulation.

The prescriber determines the exact dose and frequency based on wound size, depth and clinical assessment. Typically, a thin layer of the preparation is applied to the affected area once daily, but the regimen may be adjusted to the patient’s response and the treating clinician’s judgment.

Safety data for Iruxol Mono in pregnancy or lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the prescribing healthcare professional.

To request Iruxol Mono, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature control) and the necessary import documentation.

Iruxol Mono contains a specific collagenase enzyme that selectively targets collagen in necrotic tissue, whereas other agents such as papain‑urea or mechanical debridement rely on broader proteolytic activity or physical removal. Collagenase‑based therapy often results in more precise debridement with less damage to surrounding healthy tissue, but choice of product depends on wound characteristics and clinician preference.

Iruxol Mono should be stored at room temperature, preferably below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided with the shipment to maintain product stability.

The product is applied topically to the cleaned wound surface using a sterile applicator or gloved finger. A thin, even layer is spread over the necrotic area, avoiding healthy tissue. The wound is then covered with an appropriate dressing as directed by the treating clinician.

The most serious adverse events include severe allergic reactions such as anaphylaxis, deep tissue necrosis resulting from excessive enzymatic activity, and secondary infection at the treatment site. Prompt recognition of these signs and immediate discontinuation of therapy, followed by appropriate medical intervention, are essential.

Iruxol Mono should be avoided in patients with a known hypersensitivity to collagenase or any component of the formulation, in wounds without necrotic tissue, and in healthy skin where debridement is not required. Caution is also advised for individuals with active infections that have not been adequately treated.